April 21, 2026: BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

Collaboration aims to identify biological signatures and patient subpopulations most likely to benefit from BioAegis’ recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) — BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a strategic collaboration with Prenosis®, a leader in […] The post April 21, 2026: BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Infla